Richard Ronald 4

What Happened

• Richard Ronald, a member of Emergent BioSolutions' board of directors, received two types of equity awards on April 30, 2026: 25,344 restricted stock units (RSUs) and a derivative award of 11,296 stock options. The Form 4 reports these as awards (code A) with an acquisition price of $0.00 (typical for grants). These awards are compensation for board and committee service rather than purchases or sales of stock.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (within the required two business days).
• Reported amounts: 25,344 RSUs and 11,296 stock options; reported acquisition price $0.00 (grant).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes of note:
  • F1: RSUs — each unit converts to one share on vesting; these RSUs vest the day before the one‑year anniversary of the grant, contingent on remaining a board member.
  • F2: Options — stock options granted for board service; underlying shares vest on the same annual vesting date, subject to continued board service.
  • F3: The option count was set by taking 25% of the non-employee director compensation value and dividing by the Black‑Scholes value per option as of the grant date.
• Filing timeliness: Form 4 appears timely (filed within two business days).

Context

• These are standard annual equity awards to non-employee directors and do not represent an open‑market purchase or sale. RSUs and options are contingent on future vesting and continued board service; they give rights to receive or buy shares later rather than immediate stock ownership. For retail investors, grants are routine compensation and do not by themselves signal an insider buying or selling shares.